Acorda: Study shows Fampridine-SR improves walking in MS patients

By E. Janene Geiss

Philadelphia, Sept. 25 - Acorda Therapeutics, Inc. said Monday that statistical significance was achieved on all three efficacy criteria in the company's phase 3 clinical trial of Fampridine-SR on walking in people with multiple sclerosis.

A significantly greater proportion of people (34.8%) taking Fampridine-SR had a consistent improvement in walking speed, the study's primary outcome, compared to people taking a placebo (8.3%), the Hawthorne, N.Y., biotechnology company said in a news release.

In addition, the effect was maintained in this study throughout the 14-week treatment period and there was a statistically significant improvement in the 12-Item MS Walking Scale for walking responders versus non-responders, officials said.

Fampridine-SR is a sustained-release tablet formulation of the investigational drug fampridine. Data collected in laboratory studies found that fampridine can improve the communication between damaged nerves, which may result in increased neurological function.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.